14.6 Palliative Care, Hospice & Advance Care Planning

ABIM Internal Medicine Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 0: The ABIM Exam, Blueprint & Study Strategy

0.1 Exam Format, Question Types & the 2026 Blueprint 0.2 Eligibility, Registration, Fees & Exam-Day Logistics 0.3 Scoring, the Passing Standard & Score Reports 0.4 Building a Blueprint-Weighted Study Plan

2 Chapter 1: Cardiovascular Disease (14% of Exam)

1.1 Ischemic Heart Disease & Acute Coronary Syndromes 1.2 Antithrombotic Therapy, Secondary Prevention & Mechanical Complications of MI 1.3 Atrial Fibrillation, Atrial Flutter & Stroke Prevention 1.4 Supraventricular Tachycardias, Ventricular Arrhythmias & Bradycardias 1.5 Heart Failure: Classification, Staging & Guideline-Directed Medical Therapy 1.6 Device Therapy, HFpEF & the Cardiomyopathies 1.7 Valvular Heart Disease & Endocarditis Prophylaxis 1.8 Pericardial Disease & Acute Aortic Syndromes 1.9 Hypertension: Classification, Diagnosis & Secondary Causes 1.10 Hypertensive Crises & Dyslipidemia 1.11 Adult Congenital Heart Disease & Coarctation of the Aorta 1.12 Syncope: Reflex, Orthostatic & Cardiac Causes 1.13 Cardiac Physical Examination, Murmurs & Antithrombotic Selection

3 Chapter 2: Endocrinology, Diabetes & Metabolism (9% of Exam)

2.1 Diabetes Mellitus: Diagnosis, Glycemic Targets & Pharmacotherapy 2.2 Insulin Therapy, Hyperglycemic Emergencies & Chronic Complications 2.3 Thyroid Function Testing & Hypothyroidism 2.4 Thyrotoxicosis, Thyroid Storm & Thyroid Nodules 2.5 Adrenal & Pituitary Disorders 2.6 Hypercalcemia, Hypocalcemia & Disorders of Mineral Metabolism 2.7 Osteoporosis & Paget Disease of Bone 2.8 Ovarian, Testicular & Reproductive Endocrine Disorders 2.9 Hypoglycemia, Endocrine Tumors, Polyglandular Syndromes & Severe Hypertriglyceridemia

4 Chapter 3: Gastroenterology & Hepatology (9% of Exam)

3.1 Esophageal Disease 3.2 Stomach & Duodenal Disease and Gastrointestinal Hemorrhage 3.3 Inflammatory Bowel Disease 3.4 Celiac Disease & Irritable Bowel Syndrome 3.5 Diverticular Disease & Colorectal Cancer Screening 3.6 Viral Hepatitis, Steatotic & Alcohol-Associated Liver Disease 3.7 Cirrhosis & the Complications of Portal Hypertension 3.8 Acute Pancreatitis 3.9 Chronic Pancreatitis & Biliary Tract Disease 3.10 Inherited, Autoimmune & Drug-Induced Liver Disease 3.11 Small Intestinal Disease, Ischemia & Gastrointestinal Complications of HIV

5 Chapter 4: Infectious Disease (9% of Exam)

4.1 Lower Respiratory Tract Infections & Sepsis Syndromes 4.2 Viral Respiratory Pathogens & Tuberculosis 4.3 Central Nervous System Infections 4.4 Skin, Soft Tissue, Bone & Joint Infections 4.5 Infective Endocarditis & Cardiovascular Infection 4.6 Clostridioides difficile & Catheter-Related Bloodstream Infection 4.7 HIV Diagnosis, Antiretroviral Therapy & Prevention 4.8 Opportunistic Infections & Sexually Transmitted Infections 4.9 Fever of Unknown Origin, Neutropenic Fever & Toxic Shock 4.10 Travel-Related Illness, Vector-Borne Disease & Outbreaks 4.11 Infection Prevention, Nosocomial Infection & Postexposure Prophylaxis 4.12 Rheumatic Fever, Poststreptococcal Disease, Enteric & Hepatic Infections

6 Chapter 5: Pulmonary Disease (9% of Exam)

5.1 COPD: Diagnosis, GOLD Classification & Initial Pharmacotherapy 5.2 Interventions That Reduce COPD Mortality & Exacerbation Management 5.3 Asthma: Diagnosis, Stepwise Therapy & Status Asthmaticus 5.4 Interstitial Lung Disease & Idiopathic Pulmonary Fibrosis 5.5 Sarcoidosis, Hypersensitivity Pneumonitis & Occupational Lung Disease 5.6 Pulmonary Embolism: Diagnosis, Risk Stratification & Anticoagulation 5.7 Pulmonary Hypertension & Sleep-Disordered Breathing 5.8 Acute Respiratory Distress Syndrome & Mechanical Ventilation 5.9 Pleural Disease, Empyema & Pneumothorax 5.10 Bronchiectasis, Cystic Fibrosis & Restrictive Lung Disease 5.11 Evaluation of Cough, Dyspnea, Hemoptysis & the Solitary Pulmonary Nodule

7 Chapter 6: Rheumatology & Orthopedics (9% of Exam)

6.1 Rheumatoid Arthritis: Diagnosis & Systemic Manifestations 6.2 Antirheumatic Pharmacotherapy & the Spondyloarthropathies 6.3 Gout: Pathophysiology & Acute Management 6.4 Urate-Lowering Therapy & Calcium Pyrophosphate Deposition Disease 6.5 Osteoarthritis 6.6 Systemic Lupus Erythematosus 6.7 Systemic Sclerosis, Sjogren Syndrome & Inflammatory Myopathies 6.8 The Vasculitides 6.9 Regional Musculoskeletal Syndromes, Back Pain & Sports Injuries 6.10 Other Primary Rheumatic Disorders & Mixed Connective Tissue Disease 6.11 Osteonecrosis & Metabolic Bone Disease

8 Chapter 7: Hematology (6% of Exam)

7.1 Approach to Anemia & the Microcytic Anemias 7.2 Macrocytic, Normocytic & Hemolytic Anemias 7.3 Hemoglobinopathies, Thalassemias & Paroxysmal Nocturnal Hemoglobinuria 7.4 Platelet Disorders, Thrombocytopenia & the Bleeding Patient 7.5 Coagulation Factor Disorders, Thrombophilia & Anticoagulant Reversal 7.6 Acute Leukemias, Chronic Leukemias & Myeloproliferative Neoplasms 7.7 Lymphomas & Plasma Cell Disorders 7.8 Myelodysplastic Syndrome, Myeloproliferative Neoplasms & Porphyria 7.9 Transfusion Medicine & Late Complications of Transplantation

9 Chapter 8: Medical Oncology (6% of Exam)

8.1 Breast, Lung, Colorectal & Prostate Cancer 8.2 Oncologic Emergencies 8.3 Genitourinary & Gynecologic Malignancies 8.4 Head and Neck, Bone & Soft Tissue Cancer and Cancer of Unknown Primary 8.5 Complications of Cancer & Its Treatment 8.6 Cancer Prevention, Survivorship & Psychosocial Care

10 Chapter 9: Nephrology & Urology (6% of Exam)

9.1 Acute Kidney Injury: Staging, Etiology & Urine Microscopy 9.2 Glomerular Disorders & Nephrotic Syndrome 9.3 Nephritic Syndromes, RPGN & Indications for Renal Replacement Therapy 9.4 Chronic Kidney Disease: Staging & Progression Retardation 9.5 Complications of Chronic Kidney Disease: Anemia, CKD-MBD & Acidosis 9.6 Hyponatremia, Hypernatremia & Water Balance 9.7 Potassium Disorders & Systematic Acid-Base Analysis 9.8 Renal Tubular Acidosis & Nephrolithiasis 9.9 Prostate Disorders, Urinary Incontinence & Other Urologic Conditions 9.10 Cystic Kidney Disease, Obstructive Uropathy, Tubulointerstitial Disease & Hematuria

11 Chapter 10: Neurology (4% of Exam)

10.1 Acute Ischemic Stroke: Syndromes & Reperfusion 10.2 Transient Ischemic Attack, Secondary Prevention & Hemorrhagic Stroke 10.3 Headache & Facial Pain 10.4 Seizures, Epilepsy & Movement Disorders 10.5 Multiple Sclerosis & Neuromuscular Junction Disorders 10.6 Motor Neuron Disease & Acute Peripheral Neuropathy 10.7 Cranial Neuropathies & Neuro-Ophthalmology 10.8 Peripheral Neuropathies, CNS Tumors & Other Neurologic Disorders

12 Chapter 11: Psychiatry & Behavioral Health (4% of Exam)

11.1 Major Depressive Disorder & Medical Mimics 11.2 Antidepressant Pharmacotherapy & Treatment-Resistant Depression 11.3 Bipolar Disorder, Mood Stabilizers & Lithium Toxicity 11.4 Anxiety, Stress-Related & Obsessive-Compulsive Disorders 11.5 Alcohol Use Disorder & Withdrawal 11.6 Pharmacotherapy for Alcohol & Opioid Use Disorder 11.7 Toxidromes, Psychiatric Emergencies & Suicide Risk Assessment 11.8 Psychotic, Somatic Symptom, Factitious & Personality Disorders 11.9 Eating Disorders, Sleep Disorders & Sexual Health

13 Chapter 12: Dermatology (3% of Exam)

12.1 Dermatitis, Papulosquamous & Inflammatory Dermatoses 12.2 Acne, Rosacea & Cutaneous Infections 12.3 Herpes Zoster & Autoimmune Blistering Diseases 12.4 Nodules, Tumors & Cutaneous Oncology 12.5 Dermatologic Emergencies & Severe Cutaneous Adverse Reactions 12.6 Pigment Disorders, Alopecia, Nail Disease & Photosensitivity 12.7 Vascular Dermatoses, Environmental Injury & Cutaneous Signs of Systemic Disease

14 Chapter 13: Obstetrics & Gynecology / Women's Health (3% of Exam)

13.1 Contraception, Preconception Care & Teratogenicity 13.2 Hypertensive Disorders of Pregnancy & Gestational Diabetes 13.3 Thyroid Disease & Venous Thromboembolism in Pregnancy 13.4 Menopause & Menopausal Hormone Therapy 13.5 Abnormal Uterine Bleeding, Endometrial Disease & Gynecologic Cancer Screening 13.6 Breast Disorders & Diseases of the Vulva and Vagina 13.7 Menstrual Disorders, Fibroids, Endometriosis & Early Pregnancy Complications

15 Chapter 14: Geriatric Syndromes (3% of Exam)

14.1 Comprehensive Geriatric Assessment & Frailty 14.2 Falls, Gait Assessment & Polypharmacy 14.3 Urinary Incontinence & Pressure Injuries in Older Adults 14.4 Mild Cognitive Impairment, Dementia & Its Subtypes 14.5 Delirium & the Pharmacotherapy of Cognitive Disorders 14.6 Palliative Care, Hospice & Advance Care Planning 14.7 Chronic Wounds, Nutrition, Swallowing, Constipation & Hip Fracture 14.8 Sensory Impairment, Dizziness, Elder Mistreatment & Care Settings

16 Chapter 15: Allergy & Immunology (2% of Exam)

15.1 Anaphylaxis: Recognition & Emergency Management 15.2 Urticaria & Angioedema 15.3 Drug Allergy, Desensitization & Adult Immunodeficiency 15.4 Food Allergy, Insect Venom Hypersensitivity, Serum Sickness & Contrast Reactions 15.5 Rhinitis, Conjunctivitis, Eosinophilic & Mast Cell Disorders

17 Chapter 16: Preventive Medicine, Immunization & Clinical Epidemiology

16.1 The USPSTF Framework & Evidence-Based Cancer Screening 16.2 Cardiovascular & Metabolic Screening and Primary Prevention 16.3 Adult Immunization & Vaccines in Special Populations 16.4 Clinical Epidemiology, Biostatistics & Study Design

18 Chapter 17: Miscellaneous - Ethics, Patient Safety & Quality Improvement (2% of Exam)

17.1 Principles of Bioethics & Decisional Capacity 17.2 Informed Consent, Treatment Refusal & Special Scenarios 17.3 Surrogate Decision-Making, Advance Directives & Confidentiality 17.4 Patient Safety Science, Medical Error & Diagnostic Reasoning 17.5 Quality Improvement Methods, Health Disparities & Health Equity

19 Chapter 18: Perioperative Medicine & Medical Consultation

18.1 Preoperative Cardiovascular Risk Assessment 18.2 Preoperative Pulmonary Risk & Perioperative Medication Management 18.3 Perioperative Anticoagulation, Bridging & Postoperative Complications

20 Chapter 19: Ophthalmology (1% of Exam)

19.1 The Acute Red Eye & Ophthalmic Emergencies 19.2 Painless Vision Loss & Chronic Ophthalmic Disease 19.3 Uveitis, Scleritis & Orbital Disease

21 Chapter 20: Otolaryngology & Dental Medicine (1% of Exam)

20.1 Dizziness, Vertigo & Epistaxis 20.2 Ear Disorders, Hearing Loss & Upper Respiratory Infections 20.3 Oral Cavity, Salivary Gland, Laryngeal & Taste and Smell Disorders

14.6 Palliative Care, Hospice & Advance Care Planning

Key Takeaways Explain This Topic AI

End-of-life and palliative care of the elderly and ethics in the elderly are separately enumerated Geriatric Syndromes subsections.

Palliative care is appropriate at any stage of serious illness alongside disease-directed treatment and is not restricted by prognosis.

Hospice eligibility generally requires a prognosis of six months or less if the disease follows its expected course.

Opioid conversion between agents requires reduction for incomplete cross-tolerance when calculating the new dose.

Physician orders for life-sustaining treatment are actionable medical orders, distinct from an advance directive, which appoints a surrogate and states preferences.

Last updated: October 2026

1. Palliative Care vs. Hospice & Symptom Management
Palliative Care vs. Hospice Care: Clinical Distinctions

Palliative Care: Specialized interprofessional medical care for patients living with serious, chronic, or life-threatening illness (advanced cancer, heart failure, COPD, ESRD, ALS, dementia). The central focus is symptom management, psychosocial/spiritual support, and aligning treatments with personal goals. Palliative care is appropriate at ANY stage of disease, can begin at the time of initial diagnosis, and is delivered CONCURRENTLY with curative, life-prolonging, or disease-modifying therapies (e.g., chemotherapy, radiation, dialysis, LVAD).

Hospice Care: A specific Medicare insurance benefit and delivery model of comprehensive palliative care reserved for patients with a certified terminal prognosis of <= 6 months if the disease follows its natural course. The patient (or surrogate) elects to shift the treatment focus entirely to comfort and quality of life, foregoing curative, life-prolonging, or disease-directed therapies . Care is provided in the patient's home, nursing facility, or inpatient hospice unit, and includes bereavement support for the family for up to 1 year after the death.

Palliative Pain Management & Opioid Conversion Science
Equianalgesic Opioid Conversion Ratios

When titrating or rotating opioids for refractory pain, dose calculations must utilize validated standard equianalgesic conversion factors: Oral Morphine 30 mg = IV Morphine 10 mg ( 3 : 1 oral-to-IV ratio ) = Oral Oxycodone 20 mg ( 1.5 : 1 oral morphine-to-oxycodone ratio ) = Oral Hydromorphone 7.5 mg ( 4 : 1 oral morphine-to-hydromorphone ratio ) = IV Hydromorphone 1.5 mg ( 5 : 1 oral-to-IV hydromorphone ratio; 7 : 1 IV morphine-to-hydromorphone ) = Transdermal Fentanyl 25 mcg/hr patch ≈ 60 − 90 mg/day Oral Morphine \begin{aligned}

\text{Oral Morphine } 30\text{ mg} &= \text{IV Morphine } 10\text{ mg} \quad (3:1 \text{ oral-to-IV ratio}) \\
&= \text{Oral Oxycodone } 20\text{ mg} \quad (1.5:1 \text{ oral morphine-to-oxycodone ratio}) \\
&= \text{Oral Hydromorphone } 7.5\text{ mg} \quad (4:1 \text{ oral morphine-to-hydromorphone ratio}) \\

&= \text{IV Hydromorphone } 1.5\text{ mg} \quad (5:1 \text{ oral-to-IV hydromorphone ratio; } 7:1 \text{ IV morphine-to-hydromorphone}) \\

&= \text{Transdermal Fentanyl } 25\text{ mcg/hr patch} \approx 60-90\text{ mg/day Oral Morphine}

\end{aligned} Oral Morphine 30 mg = IV Morphine 10 mg ( 3 : 1 oral-to-IV ratio ) = Oral Oxycodone 20 mg ( 1.5 : 1 oral morphine-to-oxycodone ratio ) = Oral Hydromorphone 7.5 mg ( 4 : 1 oral morphine-to-hydromorphone ratio ) = IV Hydromorphone 1.5 mg ( 5 : 1 oral-to-IV hydromorphone ratio; 7 : 1 IV morphine-to-hydromorphone ) = Transdermal Fentanyl 25 mcg/hr patch ≈ 60 − 90 mg/day Oral Morphine

Safe Opioid Rotation Protocol (4-Step Method)

Calculate Total 24-Hour Baseline Dose: Sum all scheduled and PRN doses consumed in the preceding 24 hours.

Convert to Equianalgesic Baseline: Use conversion ratios to calculate the equivalent 24-hour dose of the new opioid.

Apply Incomplete Cross-Tolerance Reduction: Reduce the calculated daily dose by 25% to 50% (standard: 33%) to prevent fatal overdose from incomplete receptor cross-tolerance.

Formulate Breakthrough PRN Doses: Prescribe immediate-release breakthrough medication at 10% to 15% of the total 24-hour baseline scheduled dose , available every 1 to 2 hours PRN for oral agents (or every 15-30 minutes for IV PCA).

Renal Failure & Opioid Selection

Morphine & Hydromorphone: Metabolized to active glucuronide metabolites (Morphine-6-glucuronide [analgesic/sedative], Morphine-3-glucuronide [neurotoxic: hyperalgesia, myoclonus, allodynia], Hydromorphone-3-glucuronide) that accumulate in renal impairment / ESRD , causing severe toxicity.

Fentanyl & Methadone: Safest opioids in severe renal failure and ESRD ; undergo hepatic clearance without active neurotoxic renal metabolites.

Mandatory Prophylactic Bowel Regimen

Opioids bind μ \mu μ -receptors in the myenteric plexus, impairing peristalsis and mucosal secretions. Tolerance to opioid-induced constipation (OIC) NEVER develops. Every patient prescribed an opioid must be co-prescribed a scheduled prophylactic stimulant bowel regimen:

Stimulant Laxative: Senna (1-2 tablets PO daily to BID) or Bisacodyl (5-10 mg PO/PR daily) ± \pm ± Osmotic agent ( Polyethylene Glycol / PEG 3350 17 g daily).

Caution: Bulk-forming laxatives (Psyllium) are contraindicated in debilitated palliative patients due to risk of fecal impaction and bowel obstruction.

Refractory OIC: Peripherally Acting Mu-Opioid Receptor Antagonists ( PAMORAs : Methylnaltrexone 8-12 mg SC , Naloxegol 25 mg PO ); PAMORAs block peripheral bowel receptors without crossing the blood-brain barrier, reversing constipation without precipitating central opioid withdrawal or reversing analgesia.

Management of Dyspnea & Terminal Secretions

Palliative Symptom Pathophysiology & Clinical Presentation Non-Pharmacologic Management First-Line Pharmacologic Therapy

Palliative Dyspnea Subjective breathlessness in advanced cardiopulmonary disease or malignancy; mismatched ventilatory drive and mechanical capacity 1. Handheld Fan blowing cool air across trigeminal ( V 2 / V 3 V_2/V_3 V 2 / V 3 ) facial dermatomes (stimulates mechanoreceptors, dramatically reducing central perception of dyspnea).; 2. Upright positioning (orthopneic position).; 3. Pursed-lip breathing and bedside relaxation techniques. Low-Dose Opioids (Oral Morphine 2.5 to 5 mg PO q4h PRN or IV Morphine 1 to 2 mg q2h PRN) :; - Gold standard: reduces central perception of air hunger, blunts respiratory center anxiety, and improves ventilation-perfusion matching without causing hypercapnia or respiratory arrest when titrated carefully.; (Note: Supplemental Oxygen is ONLY beneficial if patient is documented to be hypoxemic [ S p O 2 < 90 % SpO_2 <90\% Sp O 2 < 90% ]; oxygen provides no added benefit over room air in non-hypoxemic dyspnea).

Terminal Secretions ("Death Rattle") Accumulation of saliva and mucus in the hypopharynx and trachea due to loss of swallowing reflex and pharyngeal muscle tone in the final hours/days of life 1. Repositioning: Turn patient onto side (lateral semi-prone recovery position) to facilitate postural gravity drainage.; 2. Gentle wiping of anterior mouth.; CONTRAINDICATION: Avoid deep tracheal or pharyngeal suctioning , which causes severe gagging, coughing, mucosal trauma, and agitation. Reassure family that secretions cause no distress to the comatose patient. Anticholinergic / Antimuscarinic Drying Agents: ; 1. Glycopyrrolate (0.2 to 0.4 mg IV/SC q4h PRN): Preferred agent because it is a quaternary amine that does NOT cross the blood-brain barrier, avoiding central delirium and hallucinations.; 2. Scopolamine Transdermal Patch (1.5 mg applied behind ear q72h) : Tertiary amine; crosses blood-brain barrier (risk of delirium).; 3. Sublingual Atropine 1% Ophthalmic Solution (1 to 2 drops SL q2-4h PRN) .

2. Advance Care Planning: Decisional Capacity & Medical Orders
The 4 Core Elements of Clinical Decisional Capacity

Decisional capacity is a clinical assessment made by any licensed physician for a specific decision at a specific point in time (unlike "competency", which is a global legal status determined solely by a judge).

To possess decisional capacity for a proposed intervention, the patient must demonstrate all 4 elements:

Understanding: Ability to comprehend the diagnosis, proposed treatment, potential risks, benefits, and reasonable alternatives (including no treatment).

Appreciation: Ability to appreciate how the medical information applies directly to their own personal health situation and future.

Reasoning: Ability to process the information logically, compare the options, and articulate rational reasons behind their decision congruent with their values.

Expressing a Choice: Ability to clearly and consistently communicate a voluntary choice (verbally, in writing, or through unambiguous gestures).

Advance Directives & Surrogacy Standards

Living Will: A legal document detailing specific medical treatments a person wishes to receive or refuse under hypothetical end-of-life circumstances (e.g., persistent vegetative state, terminal illness).

Durable Power of Attorney for Healthcare (Healthcare Proxy): Designates a specific surrogate decision-maker to make healthcare decisions if the patient loses decisional capacity.

Hierarchy of Surrogate Decision-Making:

Substituted Judgment Standard (Primary Standard): The surrogate must make the exact medical decision that the patient would have made based on known personal values, religious beliefs, and prior expressed wishes. The surrogate's personal preferences are irrelevant.

Best Interests Standard (Secondary Standard): Used ONLY when the patient's prior wishes and values are completely unknown. The surrogate and medical team decide based on what a reasonable person would choose to maximize net benefit and minimize suffering.

POLST / MOLST vs. Traditional Advance Directives

POLST (Physician Orders for Life-Sustaining Treatment) / MOLST (Medical Orders for Life-Sustaining Treatment) translate patient preferences into immediately actionable, legally binding medical orders signed by a clinician (MD/DO/NP/PA) and the patient/surrogate. They are active across all healthcare settings (home, EMS, ED, ICU).

POLST / MOLST Section Clinical Order Options Practical Board Scenarios

Section A: Cardiopulmonary Resuscitation (CPR) 1. Attempt Resuscitation / CPR ; 2. Do Not Resuscitate / DNR (No CPR) Applies ONLY when the patient is in full cardiopulmonary arrest (unresponsive, pulseless, apneic). If patient has a pulse, Section B governs care.

Section B: Medical Interventions 1. Full Treatment: Intubation, mechanical ventilation, defibrillation, ICU admission, invasive arterial/central lines.; 2. Selective / Limited Interventions: IV fluids, IV antibiotics, non-invasive positive pressure ventilation (CPAP/BiPAP), transfer to hospital; NO endotracheal intubation .; 3. Comfort-Focused Treatment: Maximizing comfort, oral pain/dyspnea medications, positioning; transfer to hospital ONLY if comfort cannot be managed at home/facility. A patient with a DNR order can still receive Full Treatment under Section B (e.g., intubation for severe pneumonia with DNR if cardiac arrest occurs). DNR does NOT mean 'do not treat'.

Section C: Artificially Administered Nutrition 1. Long-Term Feeding Tube (PEG) ; 2. Defined Trial Period of Feeding Tube ; 3. No Artificial Nutrition / Comfort Feeding by Mouth Only Feeding tubes in advanced dementia do NOT prolong survival, prevent aspiration pneumonia, improve functional status, or heal pressure ulcers. Hand-feeding for comfort is the recommended gold standard.